Total Payments
$2,306
2024 Payments
$575.54
Companies
25
Transactions
121
Medicare Patients
9,432
Medicare Billing
$3.0M
Payment Breakdown by Category
Food & Beverage$2,306 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,306 | 121 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $378.01 | 20 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $355.55 | 19 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $208.94 | 11 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $151.62 | 8 | $0 (2024) |
| ABBVIE INC. | $148.54 | 8 | $0 (2024) |
| Lilly USA, LLC | $131.49 | 6 | $0 (2024) |
| Merck Sharp & Dohme LLC | $118.08 | 7 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $114.65 | 7 | $0 (2022) |
| Shionogi Inc | $89.24 | 4 | $0 (2024) |
| Abbott Laboratories | $88.27 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $575.54 | 23 | Novartis Pharmaceuticals Corporation ($126.26) |
| 2023 | $336.55 | 17 | ABBVIE INC. ($105.92) |
| 2022 | $213.77 | 11 | AstraZeneca Pharmaceuticals LP ($124.33) |
| 2021 | $193.50 | 13 | AstraZeneca Pharmaceuticals LP ($63.40) |
| 2020 | $96.95 | 6 | AstraZeneca Pharmaceuticals LP ($23.38) |
| 2019 | $178.68 | 12 | GlaxoSmithKline, LLC. ($68.50) |
| 2018 | $416.56 | 23 | GlaxoSmithKline, LLC. ($204.75) |
| 2017 | $294.42 | 16 | GlaxoSmithKline, LLC. ($65.82) |
All Payment Transactions
121 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $29.11 | General |
| Category: Narcoplepsy | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/15/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $18.63 | General |
| Category: Narcoplepsy | ||||||
| 11/15/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| Category: Narcoplepsy | ||||||
| 11/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $31.32 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/26/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Obesity | ||||||
| 08/07/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $67.63 | General |
| Category: Hematology | ||||||
| 07/08/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/19/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/08/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/08/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/27/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Pulmonology | ||||||
| 03/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $30.07 | General |
| Category: Diabetes | ||||||
| 02/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $33.43 | General |
| Category: RESPIRATORY | ||||||
| 01/25/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: Diabetes | ||||||
| 01/18/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Airway Clearance Device | ||||||
| 12/21/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Respiratory | ||||||
| 12/02/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: INSOMNIA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,125 | 6,289 | $1.7M | $656,619 |
| 2022 | 19 | 1,968 | 6,563 | $1.4M | $667,815 |
| 2021 | 18 | 2,161 | 7,081 | $1.5M | $739,291 |
| 2020 | 24 | 3,178 | 9,600 | $1.9M | $938,565 |
Total Patients
9,432
Total Services
29,533
Medicare Billing
$3.0M
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 198 | 1,371 | $616,950 | $235,880 | 38.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 293 | 1,462 | $255,725 | $147,637 | 57.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 290 | 1,417 | $425,100 | $136,410 | 32.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 227 | 835 | $208,750 | $53,557 | 25.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 225 | 269 | $121,050 | $37,819 | 31.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 73 | 73 | $25,550 | $13,045 | 51.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 43 | $8,600 | $6,010 | 69.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 110 | 110 | $8,800 | $5,285 | 60.1% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 110 | 110 | $8,800 | $4,010 | 45.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 110 | 110 | $11,000 | $3,539 | 32.2% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 31 | 34 | $10,200 | $2,941 | 28.8% |
| 31625 | Biopsy of lung airway using an endoscope | Facility | 2023 | 18 | 21 | $11,550 | $2,608 | 22.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 80 | 80 | $3,200 | $2,549 | 79.7% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 80 | 80 | $4,000 | $1,637 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 23 | $2,875 | $1,565 | 54.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 191 | 220 | $7,920 | $1,296 | 16.4% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 31 | 31 | $3,100 | $834.00 | 26.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 186 | 1,279 | $467,750 | $228,338 | 48.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 297 | 1,754 | $306,825 | $178,116 | 58.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 271 | 1,516 | $325,700 | $126,737 | 38.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 231 | 904 | $145,250 | $52,711 | 36.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 210 | 276 | $102,550 | $44,585 | 43.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 53 | 53 | $18,550 | $9,393 | 50.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 95 | 95 | $7,600 | $4,754 | 62.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 30 | $6,000 | $3,934 | 65.6% |
About Dr. Rakesh Gupta, MD
Dr. Rakesh Gupta, MD is a Pulmonary Disease healthcare provider based in San Jacinto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871574996.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rakesh Gupta, MD has received a total of $2,306 in payments from pharmaceutical and medical device companies, with $575.54 received in 2024. These payments were reported across 121 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,306).
As a Medicare-enrolled provider, Gupta has provided services to 9,432 Medicare beneficiaries, totaling 29,533 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location San Jacinto, CA
- Active Since 11/07/2005
- Last Updated 02/17/2010
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1871574996
Products in Payments
- TRELEGY ELLIPTA (Drug) $229.17
- BREZTRI (Drug) $162.22
- ENTRESTO (Drug) $147.72
- XARELTO (Drug) $114.65
- Fetroja (Drug) $89.24
- JANUVIA (Drug) $86.35
- MOUNJARO (Drug) $85.93
- ANORO (Drug) $79.99
- FARXIGA (Drug) $79.10
- SPIRIVA RESPIMAT (Drug) $74.17
- Mitra Clip system (Device) $70.45
- ACCRUFER (Drug) $67.63
- LEQVIO (Drug) $61.22
- WAKIX (Drug) $61.08
- DALVANCE (Drug) $58.97
- STIOLTO RESPIMAT (Drug) $57.82
- LONHALA MAGNAIR (Drug) $49.11
- DUPIXENT (Biological) $47.12
- EMGALITY (Drug) $45.56
- BREO (Drug) $43.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.